Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivo800 in High Grade Glioma
NCT07210632Phase 1Recruiting
- Sponsor
- Eben Rosenthal
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nivolumab-IRDye800CW in glioma (5 arms), sponsored by Eben Rosenthal. Primary endpoint: Safety assessed via adverse events. Started Mar 2026; status: recruiting.
02
Drugs
Nivolumab-IRDye800CW
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07210632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210632.